Adverse Effects of HMG CoA Reductase Inhibitor and Garlic on Renal Function in Patients with Diabetic Dyslipidemia

被引:0
|
作者
Siddiqui, Naveed Ali [1 ]
Ishaque, Imran [2 ]
Rahat, Yousra [3 ]
Akhtar, Naheed [4 ]
Tehreem, Umaya [3 ]
Javed, Rafia [3 ]
Ali, Rayyan [3 ]
机构
[1] United Med & Dent Coll, Dept Biochem, Karachi, Pakistan
[2] United Med & Dent Coll, Dept Anat, Karachi, Pakistan
[3] United Med & Dent Coll, Karachi, Pakistan
[4] Karachi Inst Med Sceinces, Dept Anat, Karachi, Pakistan
关键词
Urea; Creatinine; Diabetic dyslipidemia; HMG-CoA reductase inhibitor; Coronary heart disease; CARDIOVASCULAR-DISEASE; FAILURE SECONDARY; LIPID PROFILE; RHABDOMYOLYSIS; SIMVASTATIN;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To analyze the adverse effects of HMG CoA reductase inhibitor (statin) and garlic (Allium sativum) on renal function in diabetic dyslipidemic patients. Methods: This clinical trial was conducted at Surgeon Munawar Memorial Hospital, Karachi from 1st March 2019 to 30th August 2019. Total of 60 patients of 30-70 years of age with abnormal lipid profile were enrolled for this study after a written consent. The study was conducted to assess the side effects of statin (20 mg/day) and garlic (300 mg/day) in diabetic dyslipidemia patients. The study period consisted of six months. Blood pressure, body weight and height of subjects were assessed. The patient answered the questionnaire on health complaints, smoking, social role, drug usage, family history and dietary pattern. The initial inclusion criteria of the patient were 1) Age between 30-70 years old of either sex, 2) Patients with diabetic dyslipidemia. The exclusion criteria were 1) Pregnancy or lactation, 2) Patients with liver diseases, 3) Patients with renal diseases. Detailed medical history and physical examination of all patients were carried out. Results: This study included 60 patients with an abnormal lipid profile of age 30-70 years. International statin product (20 mg/day) and local garlic product (300 mg/day) for 08 weeks were used for oral administration in patients. Urea and creatinine levels in the serum of diabetic dyslipidemic patients were measured before and after treatment with an international statin (20 mg/day) and a local garlic product (300 mg/day). Conclusion: According to the findings of this study, statins increase the serum level of urea and creatinine while has no effect on urea and creatinine serum level.
引用
收藏
页码:71 / 75
页数:5
相关论文
共 50 条
  • [41] THE USE OF SIMVASTATIN, AN HMG COA REDUCTASE INHIBITOR, IN OLDER PATIENTS WITH HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS
    BACH, LA
    COOPER, ME
    OBRIEN, RC
    JERUMS, G
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1990, 38 (01) : 10 - 14
  • [42] Geographic Variation in HMG-CoA Reductase Inhibitor Use in Dialysis Patients
    Wetmore, James B.
    Mahnken, Jonathan D.
    Mukhopadhyay, Purna
    Hou, Qingjiang
    Ellerbeck, Edward F.
    Rigler, Sally K.
    Spertus, John A.
    Shireman, Theresa I.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2012, 27 (11) : 1475 - 1483
  • [43] Pitavastatin, an HMG-CoA Reductase Inhibitor, Ameliorates Endothelial Function in Chronic Smokers
    Yoshida, Osamu
    Kondo, Takahisa
    Kureishi-Bando, Yasuko
    Sugiura, Tomonori
    Maeda, Kengo
    Okumura, Kenji
    Murohara, Toyoaki
    CIRCULATION JOURNAL, 2010, 74 (01) : 195 - 202
  • [44] HMG-CoA reductase inhibitor pravastatin improves endothelial function in patients with isolated low HDL cholesterol
    Higashi, Yukihito
    Nishioka, Kenji
    Umemura, Takashi
    Jitsuiki, Daisuke
    Goto, Chikiara
    Yoshizumi, Masao
    HYPERTENSION, 2007, 50 (04) : E126 - E126
  • [45] HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia
    Guan, Jing-Zhi
    Tamasawa, Naoki
    Murakami, Hiroshi
    Matsui, Jun
    Tanabe, Jutaro
    Matsuki, Kota
    Yamashita, Maki
    Suda, Toshihiro
    JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, 2008, 15 (01) : 20 - 25
  • [46] Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis
    Han, Seung Hyeok
    Kang, Ea Wha
    Yoon, Se-Jung
    Yoon, Hyang Sook
    Lee, Hyun Chul
    Yoo, Tae Hyun
    Choi, Kyu Hun
    Han, Dae-Suk
    Kang, Shin-Wook
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (11) : 3722 - 3728
  • [47] Incidence of adverse events with HMG-CoA reductase inhibitors in liver transplant patients
    Martin, Jill E.
    Cavanaugh, Teresa M.
    Trumbull, Leslie
    Bass, Maryetta
    Weber, Fredrick, Jr.
    Aranda-Michel, Jaime
    Hanaway, Michael
    Rudich, Steven
    CLINICAL TRANSPLANTATION, 2008, 22 (01) : 113 - 119
  • [48] EFFECTS OF HMG-COA REDUCTASE INHIBITORS IN HYPERCHOLESTEROLEMIC PATIENTS ON HEMODIALYSIS
    WANNER, C
    HORL, WH
    LULEY, CH
    WIELAND, H
    KIDNEY INTERNATIONAL, 1991, 39 (04) : 754 - 760
  • [49] HYPOLIPIDEMIC EFFECTS OF HMG-COA REDUCTASE INHIBITORS IN PATIENTS WITH HYPERCHOLESTEROLEMIA
    ILLINGWORTH, DR
    BACON, S
    AMERICAN JOURNAL OF CARDIOLOGY, 1987, 60 (12): : G33 - G42
  • [50] Effects of HMG-CoA reductase inhibitors on mitochondrial function in heats and livers
    Satoh, K
    Yamamoto, A
    Kaneta, S
    Ichihara, K
    JAPANESE JOURNAL OF PHARMACOLOGY, 2002, 88 : 16P - 16P